Insider · CIK 0001808592

von Moltke Lisa

Reports to the SEC for 3 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001808592

Forms 4 and 5

Insider transactions

40 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-15	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+150K sh	—	—	150,000
2025-04-15	ZBIOZenas BioPharma, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+400K sh	—	—	400,000
2025-02-18	MCRBSeres Therapeutics, Inc.S Sale	See Remarks	SSale	−4,416 sh	$0.81	−$3,579.168	39,875
2025-02-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+2,969 sh	—	—	35,384
2025-02-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+8,907 sh	—	—	44,291
2025-02-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−2,969 sh	—	—	23,750
2025-02-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−8,907 sh	—	—	26,718
2025-02-07	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+650K sh	—	—	650,000
2024-11-18	MCRBSeres Therapeutics, Inc.S Sale	See Remarks	SSale	−977 sh	$0.54	−$528.264	32,415
2024-11-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+2,969 sh	—	—	33,392
2024-11-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−2,969 sh	—	—	26,719
2024-10-28	MCRBSeres Therapeutics, Inc.S Sale	See Remarks	SSale	−4,334 sh	$0.69	−$2,991.327	30,423
2024-10-27	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+13.7K sh	—	—	34,757
2024-10-27	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−13.7K sh	—	—	0
2024-08-16	MCRBSeres Therapeutics, Inc.S Sale	See Remarks	SSale	−973 sh	$0.84	−$817.32	21,013
2024-08-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+2,969 sh	—	—	21,986
2024-08-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−2,969 sh	—	—	29,688
2024-06-04	TVRDTvardi Therapeutics, Inc.A Award	Director	AAward	+151K sh	—	—	183,009
2024-06-04	TVRDTvardi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+195K sh	—	—	195,000
2024-05-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+2,968 sh	—	—	19,956
2024-05-15	MCRBSeres Therapeutics, Inc.S Sale	See Remarks	SSale	−939 sh	$0.94	−$882.66	19,017
2024-05-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−2,968 sh	—	—	32,657
2024-02-16	MCRBSeres Therapeutics, Inc.S Sale	See Remarks	SSale	−4,400 sh	$1.08	−$4,752	16,988
2024-02-15	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+11.9K sh	—	—	21,388
2024-02-15	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−11.9K sh	—	—	35,625
2024-02-14	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+214K sh	—	—	213,750
2024-02-14	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+288K sh	—	—	287,905
2024-02-14	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	See Remarks	AAward	+35.6K sh	—	—	35,625
2023-10-30	MCRBSeres Therapeutics, Inc.S Sale	See Remarks	SSale	−4,232 sh	$1.35	−$5,713.2	9,513
2023-10-27	MCRBSeres Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+13.7K sh	—	—	13,745
2023-10-27	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−13.7K sh	—	—	13,744
2023-06-01	TVRDTvardi Therapeutics, Inc.A Award	Director	AAward	+32.4K sh	—	—	32,362
2023-06-01	TVRDTvardi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45K sh	—	—	44,961
2023-04-27	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	See Remarks	AAward	+27.5K sh	—	—	27,489
2023-02-03	MCRBSeres Therapeutics, Inc. · Restricted Stock UnitsA Award	See Remarks	AAward	+47.5K sh	—	—	47,500
2023-02-03	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+95K sh	—	—	95,000
2023-01-02	TVRDTvardi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+45.8K sh	—	—	45,841
2022-02-04	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+175K sh	—	—	175,000
2021-02-04	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+110K sh	—	—	110,000
2020-04-06	MCRBSeres Therapeutics, Inc. · Stock Option (Right to Buy)A Award	See Remarks	AAward	+325K sh	—	—	325,000

Recent filings

Accepted (ET)
Jun 174
von Moltke Lisa0001104659-26-075254
SEC(opens sec.gov)
Apr 174
von Moltke Lisa0001104659-25-035996
SEC(opens sec.gov)
Feb 194
von Moltke Lisa0000950170-25-023569
SEC(opens sec.gov)
Feb 114
von Moltke Lisa0000950170-25-017911
SEC(opens sec.gov)
Nov 194
von Moltke Lisa0000950170-24-128626
SEC(opens sec.gov)
Oct 294
von Moltke Lisa0000950170-24-118424
SEC(opens sec.gov)
Aug 194
von Moltke Lisa0000950170-24-098717
SEC(opens sec.gov)
Jun 64
von Moltke Lisa0001415889-24-015763
SEC(opens sec.gov)
May 174
von Moltke Lisa0000950170-24-062061
SEC(opens sec.gov)

Companies

Address

C/O ZENAS BIOPHARMA, INC. 852 WINTER ST., SUITE 250

WALTHAM, MA, 02451